康哲藥業(867.HK)標普CSA-ESG評分大幅提升,位列全球同業領先水平
近日,標準普爾全球企業可持續發展評估 (標普CSA)發佈康哲藥業2022年環境、社會及管治(ESG)表現評分,康哲藥業標普CSA得分再次顯著提升,由2021年的36分提升至53分,超過全球92%的參評同業,且大幅領先行業平均得分,充分體現了康哲藥業積極將ESG管治融入集團戰略發展和業務經營的突出成果。
標普CSA由標普全球(S&P Global)發起,是全球首屈一指的企業可持續發展評估工具。其通過分析企業經濟、公司治理、環境保護、社會責任等多維度指標,對企業可持續發展表現,以及對潛在風險和機遇的識別和管控能力進行綜合審評,已被各利益相關方視為商業或投資決策的重要參考依據之一。

康哲藥業以完善且科學高效的ESG管治架構為基礎,積極踐行可持續發展理念,不斷提升自身ESG綜合治理水平。在此次標普CSA-ESG評分中,康哲藥業的多項議題得分顯著提升,包括人權和員工職業健康與安全、供應鏈管理、產品質量管理、信息與網絡安全、環境政策和管理、解決藥物成本負擔和提高藥物可及性等,且在營銷實踐、產品質量管理、解決藥物成本負擔三項議題中取得十分出色的成績。
康哲藥業立足合規運營,以健全的內部管治體系,持續建設廉潔、高效、開放的運營文化;不斷夯實創新產品孵化平台,充分發揮自身優勢,以多元合作研發,構建互惠共贏的醫療創新生態圈,提升醫藥創新研發效率,持續為患者提供可及、可負擔的高質量產品。康哲藥業稱,未來將繼續秉持高度的企業使命感和責任感,不斷提升內部治理、環境管控和社會責任實踐,推進ESG理念與集團宏觀戰略的深度融合,致力於成為國內領先的可持續發展醫藥企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.